Hybutimibe
Latest Information Update: 03 Dec 2024
Price :
$50 *
At a glance
- Originator Hanhui Pharmaceutical
- Class Cardiovascular therapies
- Mechanism of Action NPC1L1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Hypercholesterolaemia
Most Recent Events
- 30 Mar 2023 Adverse events and efficacy data from a phase III trial in Hypercholesterolemia released by Hanhui Pharmaceuticals
- 01 Jun 2022 Registered for Hypercholesterolaemia (Combination therapy) in China (PO), a first global approval
- 01 Jun 2022 Registered for Hypercholesterolaemia (Monotherapy) in China (PO), a first global approval